• Leadership Team

  • Board of Directors

  • Dame Louise Makin

    Chief Executive Officer

    Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004. She is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, an Honorary Fellow of St. John’s College, Cambridge and a member of the 30% Club.

    From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.

    Read More
    Dame Louise Makin

    Duncan Kennedy

    Chief Financial Officer

    Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and in April 2012 he joined the Leadership Team as Group Director of Finance, with management responsibility for the global finance function. Duncan led BTG's Interventional Oncology business from May 2015 until he began as CFO in January 2018.

    Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.

    Read More
    Duncan Kennedy

    Jamie Heath

    Chief Development Officer

    Jamie Heath joined BTG in 2018 as Chief Development Officer, leading the development of BTG’s overall corporate strategy, including M&A plans, growth opportunities and digital activities.

    Prior to joining BTG, Jamie was a Managing Director with Deutsche Bank where he represented select medtech, medical device and pharma companies. His career spans over 20 years in investment banking, providing strategic and financial advisory services to clients globally.

    Read More
    Jamie Heath

    John Sylvester

    Chief Commercial Officer

    John Sylvester joined BTG in January 2011, following the acquisition of Biocompatibles. John joined Biocompatibles in 2005 and was appointed to the Board in the same year.

    His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.

    Read More
    John Sylvester

    Peter Pattison

    Head of Interventional Oncology

    Peter Pattison became head of BTG's Interventional Oncology business in January 2018. He joined BTG in July 2013 following the acquisition of TheraSphere from Nordion Inc.

    At Nordion, Peter held a series of senior commercial roles, most recently Vice President of Sales, Marketing and Business Development for the company’s Targeted Therapies division that included TheraSphere. Prior to working at Nordion, Peter served as General Manager for the Asian/American Discovery Pharmacology business unit at MDS Pharma Services, a global Contract Research Organization. Peter started his career at Roche in Switzerland.

    Read More
    Peter Pattison

    Anthony Higham

    Head of Manufacturing & Supply
    Head of Pharmaceuticals & US Commercial Operations

    Anthony Higham joined BTG in January 2011 with responsibility for leading the global Manufacturing and Supply organisation; today in addition to these responsibilities Anthony also heads our Pharmaceutical business.

    He has previously held a number of international and senior Operational and Technical roles at SmithKline Beecham, GlaxoSmithKline and Aesica Pharmaceuticals. Anthony has a BSc in Biological Sciences, BEng and MSc in Manufacturing Systems Engineering and a MSt awarded by the Institute of Manufacturing, Cambridge University.

    Read More
    Anthony Higham

    Yvonne Rogers

    Head of Human Resources

    Yvonne Rogers joined BTG in December 2008 following the merger of BTG and Protherics. She joined Protherics in November 2003 to build Protherics’ Human Resources and Learning and Development activities across the global company.

    Before joining Protherics she held senior roles at Troika UK Limited, KPMG, The Mitsubishi Bank and House of Fraser. A graduate of the Chartered Institute of Personnel and Development, she has spent over 20 years as a generalist Human Resources professional.

    Read More
    Yvonne Rogers

    Paul Mussenden

    General Counsel, Head of Strategic Affairs
    Company Secretary
    Head of PnuemRx

    Joining BTG in 2000, Paul has over 20 years’ experience working with companies in the healthcare industry at all stages of development. He is Group General Counsel, Head of Strategic Affairs & Company Secretary.

    As a member of the executive Leadership Team Paul is accountable for the Legal, Intellectual Property, Market Access and Healthcare Compliance functions. He is also responsible for management oversight of the PneumRx business. He has extensive experience of supporting the establishment of corporate governance & risk management frameworks; Corporate Finance; Mergers & Acquisitions (private & public); fundraisings and investment (equity, private equity & debt); IP licensing & business development; supporting drug and medical device research, development, manufacturing & commercialization; complex litigation and dispute resolution.

    Paul has a BSc(Hons) in Biotechnology and a Ph.D in molecular biology and microbial physiology. Having qualified as a solicitor with Norton Rose Fulbright before joining BTG, Paul focused for a number of years in the area of corporate finance and corporate development before moving to the Equity Markets Group of the London Stock Exchange focusing on healthcare company transactions. 

    Paul is also a non-executive director and trustee of the charity LifeArc Limited, a business focused on the translation of R&D innovation into commercial products to better human health.

    Read More
    Paul Mussenden

    Paul McCubbin

    Head of Strategy

    Paul McCubbin, MA, D Phil, ACA, joined BTG in 2001, working initially in the Corporate Venturing team and became head of that business unit in 2004. Since then he has taken on a succession of operational roles at BTG. In 2009 he was appointed General Manager of Varithena®, and became the Head of Varithena® in April 2013, following submission of a new drug application for the product in the US.

    Prior to joining BTG, Paul was the Finance Director of Profiad Limited, a CRO spun-out of GlaxoWellcome. Previously, he led the corporate finance team in Ernst & Young’s life sciences group, advising early stage companies on strategy, partnering and fundraising. Paul qualified as a chartered accountant in 1995, whilst working in the corporate recovery and turnaround divisions at Arthur Andersen. Paul gained his degree and doctorate in biological sciences from the University of Oxford and worked as an MRC post-doctoral research fellow at Manchester University.

    Read More
    Paul McCubbin

    Peter Stratford

    Head of Innovation

    Peter Stratford joined BTG in January 2011, following the acquisition of Biocompatibles. Peter joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and transitioned the Group to the current oncology products focus.

    He joined the Cardiovascular Division Management Team at its creation in 1993, after completion of development work in contact lens application. Peter has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.

    Read More
    Peter Stratford
  • Garry Watts

    Chairman

    Garry Watts, FCA, MBE joined the Board a Chairman in January 2012. He is Chairman of the Nomination Committee.

    Other directorships: Garry is Chairman of Spire Healthcare and of Foxtons Group plc. and is a non-executive director of Coca-Cola Enterprises, Inc.

    Expertise and experience: Garry provides considerable commercial leadership experience and expertise to the BTG Board. For seven years up to December 2010, he was CEO of SSL International plc and before that its CFO. He was previously an executive director of Celltech plc and of Medeva plc, and a non-executive director of Protherics PLC and of Stagecoach Group plc. Other roles have included 17 years as a member of the UK Medicines and Healthcare Products Regulatory Agency Supervisory Board. Garry is a former partner at KPMG.

    Read More
    Garry Watts

    Dame Louise Makin

    Chief Executive Officer

    Dame Louise Makin MA, PhD (Cantab), MBA, DBE joined BTG as Chief Executive Officer in October 2004.

    Other directorships: Louise is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust. She is a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, an Honorary Fellow of St. John’s College, Cambridge and a member of the 30% Club.

    Expertise and experience: Louise is a highly experienced international business leader, who brings considerable strategic and operational expertise to the Board. Prior to joining BTG she was from 2001, President, Biopharmaceuticals Europe of Baxter Healthcare, with responsibility for Europe, Africa and the Middle East. Before Baxter, Louise was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles during 13 years at ICI.
    Read More
    Dame Louise Makin

    Duncan Kennedy

    Chief Financial Officer

    Duncan Kennedy joined the Board as Chief Financial Officer in January 2018.

    Other directorships: Duncan currently holds no external directorships.

    Expertise and experience: Duncan provides significant financial expertise to the Board. Before being appointed CFO, Duncan led BTG’s Interventional Oncology business, a role he has held since May 2015. Duncan joined BTG in December 2005 as Group Financial Controller and became a member of the Leadership Team in April 2012 when he was appointed Group Director of Finance, with responsibility for managing the global finance function and supporting the CFO. Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University

    Read More
    Duncan Kennedy

    Gregory Barrett

    Non-executive director

    Gregory Barrett was appointed to the Board in January 2018.

    Other directorships: Gregory is currently a non-executive director of Cutera Inc. and currently sits on the Board of Aqua Medical. Past Board positions include Chairman roles at Monteris Medical and Barrx Inc

    Expertise and experience: Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery divisions of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.

    Read More
    Gregory Barrett

    Dr. Susan Foden

    Non-executive director

    Dr. Susan Foden, MA, DPhil was appointed to the Board March 2015. She is Chairman of the Remuneration Committee and a member of the Nomination Committee. 

    Other directorships: Susan currently holds non-executive roles with BerGenBio ASA, Evgen Pharma plc and Vectura Group plc, and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund.

    Expertise and experience: Susan brings extensive industry experience to the BTG Board with a strong track record of having assisted in the development of a number of businesses in the sector. She was Investor Director with the venture capital firm Merlin Biosciences, was formerly CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and was Head of Academic Liaison at Celltech Ltd.

    Read More
    Dr. Susan Foden

    Graham Hetherington

    Non-executive director

    Graham Hetherington was appointed to the Board in August 2016. He is the Company’s Senior Independent Director and is Chairman of the Audit Committee and a member of the Remuneration Committee 

    Other directorships: Graham currently holds no other directorships.

    Expertise and experience: Graham brings substantial financial and industry experience to the BTG Board. Prior to joining BTG he was Chief Financial Officer of Shire plc, a role he held from June 2008 to February 2014. Previously he held the same positions at Bacardi in 2007 and at Allied Domecq PLC from 1999 to 2005. Graham has a broad knowledge of international finance management and planning, including M&A, audit and risk management and is a Fellow of the Chartered Institute of Management Accountants.

    Read More
    Graham Hetherington

    Ian Much

    Non-executive director

    Ian Much was appointed to the Board in August 2010. He is a member of the Audit, Remuneration and Nomination Committees. 

    Other directorships: Ian currently holds no other directorships.

    Expertise and experience: Ian provides substantial international business experience to the Board. He was Chief Executive of De La Rue plc between 1998 and 2004 and Chief Executive of T&N plc between 1996 and 1998. Previously he was non-executive director of Manchester United plc, Camelot plc, Admiral plc, and Chemring Group plc.

    Read More
    Ian Much

    Jim O’Shea

    Non-executive director

    Jim O’Shea was appointed to the Board in April 2009. He is a member of the Nomination Committee. 

    Other directorships: Jim serves as Chairman of Cardiome Pharma, is a director of Trevi Therapeutics, Inc., and Ocular Therapeutix™.

    Expertise and experience: Jim provides the Board with significant US Industry experience. He is a former Chairman of the US National Pharmaceuticals Council. From 2007 to 2008, he was Vice Chairman of Sepracor, Inc., where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he held several management positions of increasing responsibility in international sales and marketing in the US and the UK.

    Read More
    Jim O’Shea

    Anne Thorburn

    Non-executive director

    Anne Thornburn was appointed to the Board in January 2018. She is a member of the Audit Committee. 

    Other directorships: Anne is non-executive director and Chair of the Audit Committee of Diploma PLC.

    Expertise and experience: Anne has an extensive range of international financial management, risk, audit and M&A experience. She was Chief Financial Officer of Exova Group plc from 2009 to 2015 and previously served as Group Finance Director at British Polythene Industries PLC. Anne is a member of the Institute of Chartered Accountants in Scotland.

    Read More
    Anne Thorburn

    Richard Wohanka

    Non-executive director

    Richard Wohanka was appointed to the Board in January 2013. He is a member of the Audit and Remuneration Committees. 

    Other directorships: Richard is a board member of Lloyds Banking Group Insurance (Scottish Widows), Julius Baer International Limited and Chairman of the Nuclear Liabilities Fund and of Old Mutual Global Investors.

    Expertise and experience: Richard provides substantial expertise to the BTG Board in the field of business and finance, with more than twenty years' experience in building asset management businesses. He was CEO of Union Bancaire Privée Asset Management between October 2009 and June 2012, and from 2001 to 2009 he was CEO of Fortis Investment Management.

    Read More
    Richard Wohanka